Called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) and funded by the drug giant Novartis, the trial also found fewer cases of lung cancer in those on the treatment, rekindling
basic research findings hinting that the same inflammatory pathway may initiate or spur the growth of such tumors.
The trial also recorded fewer cases of lung cancer in those on the treatment, consistent with
basic research findings hinting that the same inflammatory pathway may initiate or spur tumor growth.
Not exact matches
Our
research found that the average cost for a
basic policy was about $ 1,259 for the driver we used as our benchmark - but this barely
hints at the wide range of costs.